Yasushi Nagasaki CPA, CPA Net Worth

Mr. Yasushi Nagasaki CPA, CPA biography

Yasushi Nagasaki CPA, CPA is the Chief Financial Officer at Emmaus Life Sciences Incorporation.

What is the salary of Mr CPA?

As the Chief Financial Officer of Emmaus Life Sciences Incorporation, the total compensation of Mr CPA at Emmaus Life Sciences Incorporation is $240,000. There are 1 executives at Emmaus Life Sciences Incorporation getting paid more, with Dr. Yutaka Niihara M.D., M.P.H, M.P.H. having the highest compensation of $385,000.

How old is Mr CPA?

Mr CPA is 54, he's been the Chief Financial Officer of Emmaus Life Sciences Incorporation since . There are 11 older and 2 younger executives at Emmaus Life Sciences Incorporation. The oldest executive at Emmaus Life Sciences Incorporation is Ian Zwicker, 71, who is the Director.

What's Mr CPA's mailing address?

Yasushi's mailing address filed with the SEC is 21250 HAWTHORNE BLVD., SUITE 800, , TORRANCE, CA, 90503.

Insiders trading at Emmaus Life Sciences Incorporation

Over the last 5 years, insiders at Emmaus Life Sciences Incorporation have traded over $1,625 worth of Emmaus Life Sciences Incorporation stock and bought 2,618,727 units worth $3,075,792 . The most active insiders traders include Yutaka Niihara, Willis C Lee a Seah H. Lim. On average, Emmaus Life Sciences Incorporation executives and independent directors trade stock every 10 days with the average trade being worth of $325. The most recent stock trade was executed by Willis C Lee on 26 February 2024, trading 115,200 units of EMMA stock currently worth $14,976.

What does Emmaus Life Sciences Incorporation do?

emmaus life sciences, inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of innovative treatments and therapies primarily for rare and orphan disease. we are initially focusing our product development efforts in sickle cell disease, a genetic disorder. our lead product candidate is an oral pharmaceutical grade l-glutamine treatment that demonstrated positive clinical results in our completed phase 3 clinical trial for sickle cell anemia and sickle ß0-thalassemia.

Emmaus Life Sciences Incorporation executives and stock owners

Emmaus Life Sciences Incorporation executives and other stock owners filed with the SEC include:

• Dr. Yutaka Niihara M.D., M.P.H, M.P.H.,
  Chairman & CEO
• Yasushi Nagasaki CPA, CPA,
  Chief Financial Officer
• Willis C. Lee M.S.,
  Vice Chairman & COO
• Ian Zwicker,
  Director
• Wei Peu Zen,
  Director
• Jane Wood,
  Director
• Masaharu Osato,
  Director
• Robert Dickey,
  Director
• Yasushi Nagasaki,
  Interim Chief Financial Officer
• Willis Lee,
  Vice Chairman of the Board, Chief Operating Officer
• Lan Tran,
  President, Chief Administrative Officer
• Yutaka Niihara,
  Chairman of the Board, Chief Executive Officer
• S. Steven Lee,
  Independent Consultant
• Kurt H. Kruger M.B.A., M.S.,
  Consultant
• Dr. Charles W. Stark Pharm.D., Pharm.D,
  Sr. VP of Medical Affairs, Clinical, Regulatory
• Dale E. Short J.D.,
  Gen. Counsel
• George Sekulich,
  Sr. VP of Global Commercialization & Chief Information Officer
• Charles William Stark,
  CSO & EVP Clinical Development
• Seah H. Lim,
  Director
• Alfred Fu Kong Lui,
  Director
• George Sekulich,
  Co-President & CCO